EPS for Spire (SR) Expected At $0.40, Last Week Tetraphase Pharmaceuticals (TTPH) Analysts

July 21, 2017 - By Richard Conner

Analysts expect Spire Inc (NYSE:SR) to report $0.40 EPS on August, 2.They anticipate $0.07 EPS change or 21.21% from last quarter’s $0.33 EPS. SR’s profit would be $19.60 million giving it 44.91 P/E if the $0.40 EPS is correct. After having $2.38 EPS previously, Spire Inc’s analysts see -83.19% EPS growth. About 54,681 shares traded. Spire Inc (NYSE:SR) has risen 11.86% since July 21, 2016 and is uptrending. It has underperformed by 4.84% the S&P500.

Among 12 analysts covering Tetraphase Pharmaceuticals (NASDAQ:TTPH), 3 have Buy rating, 0 Sell and 9 Hold. Therefore 25% are positive. Tetraphase Pharmaceuticals had 18 analyst reports since August 6, 2015 according to SRatingsIntel. BMO Capital Markets initiated the shares of TTPH in report on Tuesday, April 12 with “Market Perform” rating. Robert W. Baird downgraded Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) rating on Wednesday, September 9. Robert W. Baird has “Neutral” rating and $10 target. The firm has “Hold” rating given on Wednesday, September 9 by Brean Capital. The rating was downgraded by JMP Securities on Wednesday, September 9 to “Market Perform”. The firm has “Neutral” rating given on Wednesday, September 9 by Wedbush. BMO Capital Markets maintained Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) rating on Wednesday, June 21. BMO Capital Markets has “Buy” rating and $11.7600 target. Nomura downgraded the shares of TTPH in report on Wednesday, September 9 to “Neutral” rating. Stifel Nicolaus maintained it with “Buy” rating and $57 target in Thursday, August 6 report. The stock of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) earned “Buy” rating by SunTrust on Thursday, November 19. On Wednesday, September 9 the stock rating was downgraded by Needham to “Hold”. See Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) latest ratings:

11/07/2017 Broker: H.C. Wainwright Rating: Buy New Target: $15 Initiates Coverage On
21/06/2017 Broker: BMO Capital Markets Rating: Buy New Target: $11.7600 Maintain
10/03/2017 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Outperform Old Target: $6.00 New Target: $10.00 Upgrade

Among 3 analysts covering Spire (NYSE:SR), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Spire had 3 analyst reports since August 19, 2016 according to SRatingsIntel. The firm earned “Neutral” rating on Friday, August 19 by Ladenburg Thalmann. The firm has “Neutral” rating given on Wednesday, January 25 by Credit Suisse. The firm has “Market Perform” rating by Wells Fargo given on Tuesday, September 6.

Spire Inc., formerly The Laclede Group, Inc., is engaged to transform its business and pursue growth by growing its gas utility business through prudent investment in infrastructure upgrades and organic growth initiatives; acquire and integrate gas utilities; modernize its gas assets, and invest in innovation. The company has market cap of $3.52 billion. The Firm has two business divisions, which include gas utility and gas marketing. It has a 21.91 P/E ratio. The gas utility segment includes the regulated activities of Laclede Gas Company , Alabama Gas Corporation (Alagasco) and EnergySouth, Inc. (EnergySouth).

Since March 15, 2017, it had 1 buying transaction, and 0 sales for $82,370 activity. 11,000 shares were bought by GAGE L PATRICK, worth $82,370 on Wednesday, March 15.

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $353.30 million. The Firm uses its chemistry technology to create antibiotics for multidrug-resistant infections. It currently has negative earnings. The Firm is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Investors sentiment increased to 1.29 in 2016 Q4. Its up 0.17, from 1.12 in 2016Q3. It increased, as 12 investors sold Tetraphase Pharmaceuticals Inc shares while 22 reduced holdings. 12 funds opened positions while 32 raised stakes. 17.45 million shares or 11.89% less from 19.80 million shares in 2016Q3 were reported. Vanguard Gp Inc has 0% invested in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Meeder Asset Mgmt has invested 0% in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Credit Suisse Ag accumulated 23,327 shares or 0% of the stock. Joel Isaacson Ltd Limited Liability Company holds 5,000 shares. State Board Of Administration Of Florida Retirement Systems stated it has 19,717 shares or 0% of all its holdings. Bank Of America De reported 11,968 shares or 0% of all its holdings. Rock Springs Management Ltd Partnership stated it has 0.19% in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). The Michigan-based Dow Chem De has invested 0.03% in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Kcg Holdings Inc has invested 0.01% in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Jpmorgan Chase & owns 12,281 shares for 0% of their portfolio. Millennium Management Limited Liability reported 157,429 shares stake. Barclays Public Limited Company reported 33,688 shares stake. Wells Fargo Co Mn invested in 141,966 shares. Blackrock Fund Advisors accumulated 1.22 million shares. Acadian Asset Management Lc owns 182,027 shares for 0% of their portfolio.

About 441,759 shares traded or 4.02% up from the average. Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has risen 106.58% since July 21, 2016 and is uptrending. It has outperformed by 89.88% the S&P500.